Business
Dermata Therapeutics Provides Corporate Update and Reports Full Year 2021 Financial Results
DMT310 Phase 2 rosacea trial is over two-thirds enrolled with topline results expected in H2 2022DMT310 Phase 2 psoriasis trial to start H1 2022, with topline
About this update from Dermata Therapeutics, Inc.
[{"type":"text","content":"DMT310 Phase 2 rosacea trial is over two-thirds enrolled with topline results expected in H2 2022DMT310 Phase 2 psoriasis trial to start H1 2022, with topline results expected in H1 2023DMT310 Phase 3 moderate-to-severe acne trials planned for H1 2023SAN DIEGO, CA / ACCESSWIRE / March 28, 2022 / Dermata Therapeutics, Inc. (NASDAQ:DRMA; DRMAW) (\"Dermata\" or the \"Company\"), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today highlighted recent corporate progress and reported financial results for the year ended December 31, 2021.\"We continue to make excellent progress with the clinical programs for DMT310, our once weekly topical product derived from a naturally sourced freshwater sponge. In October 2021, we announced positive results from a Phase 1b proof of concept clinical trial in mild-to-moderate psoriasis patients. In November 2021, we initiated a Phase 2 trial in moderate-to-severe rosacea patients, where we believe DMT310's anti-inflammatory properties can demonstrate a clinical effect on the inflammatory lesions of rosacea, similar to the clinical effects we have seen in our Phase 2 acne studies. We expect to complete enrollment for this Phase 2 trial in moderate-to-severe rosacea in the first half of 2022 and expect to announce topline results in the second half of 2022,\" commented Gerry Proehl, Dermata's Chairman, President, and Chief Executive Officer. \"Additionally, we now have FDA guidance on the trials and trial designs required for an End of Phase 2 meeting with the FDA for moderate-to-severe acne, which we believe we can leverage for our other DMT310 clinical programs,\" concluded Mr. Proehl.\"For DMT410, our combination product with botulinum toxin Type A, we completed a Phase 1b study in facial aesthetics with demonstrated improvements in several aesthetic measures that we believe continue to have a high unmet need. Successfully delivering botulinum toxin to the dermis through topical administration has been a target for many years and we believe DMT410 has demonstrated an ability to do just that,\" stated Chris Nardo, Ph.D., Dermata's Senior Vice President of Development. \"With a topical application of DMT410, we were able to see a reduction in the number and size of pores, a reduction in fine lines, and a reduction in sebum production. In add...